FDA Approves Alere's HIV Test - Analyst Blog

By
A A A

Alere Inc. ( ALR ) has won the U.S. Food and Drug Administration (FDA) clearance for its Alere Determine HIV 1/2 Ag/Ab Combo test used to identify HIV-1 p24 antigen and antibodies to HIV-1/HIV-2. The company's new offering is the first and only FDA-approved test in the market. This rapid point-of-care test is superior to the second and third generation antibody-only tests and can detect HIV more effectively.

HIV, a fatal health issue, is affecting the U.S. as well as other regions. According to the Centers of Disease Control and Prevention (CDC), about 18% of the 1.4 million Americans with HIV are undiagnosed. The center also stated that approximately 47,500 new individuals have been infected with the virus in 2010.

Mass.-based Alere aims to be the leader in rapid 'near-patient' or point-of-care testing (POCT) or diagnostics. The FDA approval of Alere's latest point-of-care test is a significant step toward the eradication of HIV from the U.S., as it helps to diagnose the disease at an early stage and can assist in breaking the infection cycle. The FDA has approved the product to be sold as a CLIA (Clinical Laboratory Improvement Amendments) moderately complex medical device.


Recently, the company received a FDA approval for its Alere MobileLink. The new connected device technology allows quick data delivery from patient's home settings to their healthcare provider. The Alere MobileLink is already CE-Marked and will be rolled out in Europe and the U.S. toward the back end of this year.

ALR has a Zacks Rank #1 (Strong Buy). On Jul 31, the company reported adjusted earnings per share of 59 cents for the second quarter of 2013. The results were up 40.5% on a year-over-year basis, and beat the Zacks Consensus Estimate by a significant margin of 19 cents. Net revenue grew 9.1% to $764.0 million, exceeding the Zacks Consensus Estimate of $722 million.

Other medical stocks such as Hanger ( HGR ), Cyberonics ( CYBX ) and Thoratec ( THOR ) are worth considering. All these stocks carry a Zacks Rank #1 (Strong Buy).



ALERE INC (ALR): Free Stock Analysis Report

CYBERONICS INC (CYBX): Free Stock Analysis Report

HANGER ORTHOPED (HGR): Free Stock Analysis Report

THORATEC CORP (THOR): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.




This article appears in: Investing , Business , Stocks

Referenced Stocks: ALR , CYBX , HGR , THOR

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

75,427,639
  • $56.25 ▼ 1.58%
59,508,841
  • $16.67 ▼ 0.42%
47,696,026
  • $24.66 ▼ 0.64%
37,965,797
  • $3.80 ▼ 2.56%
29,288,629
  • $8 ▲ 0.25%
28,960,650
  • $131.78 ▼ 0.20%
26,875,249
  • $18.27 ▲ 1.56%
26,002,126
  • $34.01 ▲ 0.89%
As of 5/28/2015, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com